Join to view full profile
Medical Oncology and Therapeutics Research1500 East Duarte RoadDuarte, CA 91010
Phone+1 626-256-4673
Dr. Fakih is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 1998 - 2001
Wayne State University School of MedicineResidency, Internal Medicine, 1992 - 1995
American University of Beirut Faculty of MedicineClass of 1992
Certifications & Licensure
CA State Medical License 2012 - 2027
MI State Medical License 1994 - 2015
NY State Medical License 2002 - 2011
PA State Medical License 1997 - 2002
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2014-2017
- CMS Meaningful Use Stage 1 Certification Sunrise Acute Care, Allscripts, 2014-2017
- CMS Meaningful Use Stage 2 Certification Sunrise Ambulatory Care, Allscripts, 2014-2017
Clinical Trials
- A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation Start of enrollment: 2023 Jul 12
Roles: Contact
- Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors Start of enrollment: 2021 Apr 11
Roles: Contact
- Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy Start of enrollment: 2023 May 11
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Impact of Systematic Discontinuation of Mitomycin C HIPEC for Colorectal Peritoneal Metastases on Oncologic Outcomes: A Propensity Score-Matched Analysis.M Daniyal Tanweer, Muhammad Talha Waheed, Isaac B Paz, Thinzar Lwin, Hamza Mohammed
Annals of Surgical Oncology. 2026-10-07 - A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers.Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie
Cancer Research Communications. 2026-10-01 - 1 citationsWerner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial.Timothy A Yap, Elisa Fontana, Natalie Cook, Marwan Fakih, Oliver Bechter
Nature Medicine. 2026-09-29
Press Mentions
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025July 25th, 2025- Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDAJuly 15th, 2025
- Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (Pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 22nd, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
